Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SynCo Bio Partners has signed a master services agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells.
Subscribe to our email newsletter
Under the agreement, SynCo will fill and finish batches of OncoMed’s lead product, antibody OMP-21M18, for use in Phase I clinical trials. SynCo will fill and finish antibody at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment.
Paul Hastings, president and CEO of OncoMed, said: “We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organization that had a proven track record in filling biologics. With SynCo’s expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development.”